PuSH - Publikationsserver des Helmholtz Zentrums München

Current and future approaches for in vitro hit discovery in diabetes mellitus.

Drug Discov. Today 27:103331 (2022)
Verlagsversion Postprint DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Type 2 diabetes mellitus (T2DM) is a serious public health problem. In this review, we discuss current and promising future drugs, targets, in vitro assays and emerging omics technologies in T2DM. Importantly, we open the perspective to image-based high-content screening (HCS), with the focus of combining it with metabolomics or lipidomics. HCS has become a strong technology in phenotypic screens because it allows comprehensive screening for the cell-modulatory activity of small molecules. Metabolomics and lipidomics screen for perturbations at the molecular level. The combination of these data-intensive comprehensive technologies is enabled by the rapid development of artificial intelligence. It promises a deep cellular and molecular phenotyping directly linked to chemical information about the applied drug candidates or complex mixtures.
Impact Factor
Scopus SNIP
Altmetric
8.369
1.920
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Bioactives ; Cell Painting ; Drug Discovery ; Functional Metabolomics ; High-content Screening ; Lipidomics
Sprache englisch
Veröffentlichungsjahr 2022
HGF-Berichtsjahr 2022
ISSN (print) / ISBN 1359-6446
e-ISSN 1878-5832
Zeitschrift Drug discovery today
Quellenangaben Band: 27, Heft: 10, Seiten: , Artikelnummer: 103331 Supplement: ,
Verlag Elsevier
Verlagsort Cambridge
Begutachtungsstatus Peer reviewed
POF Topic(s) 30202 - Environmental Health
Forschungsfeld(er) Environmental Sciences
PSP-Element(e) G-504800-001
PubMed ID 35926826
Erfassungsdatum 2022-09-02